Abstract |
Despite impressive clinical success, cancer immunotherapy based on immune checkpoint blockade remains ineffective in colorectal cancer (CRC). Stimulator of interferon genes ( STING) is a novel potential target and STING agonists have shown potential anti- tumor efficacy. Combined therapy based on synergistic mechanism can overcome the resistance. However, STING agonists-based combination therapies are deficient. We designed different immunotherapy combinations, including STING agonist, indoleamine 2,3 dioxygenase (IDO) inhibitor and PD-1 blockade, with purpose of exploring which option can effectively inhibit CRC growth. To further explore the possible reasons of therapeutic effectiveness, we observed the combination therapy in C57BL/6Tmem173gt mice. Our findings demonstrated that STING agonist diABZI combined with IDO inhibitor 1-MT significantly inhibited tumor growth, even better than the three- drug combination, promoted the recruitment of CD8+ T cells and dendritic cells, and decreased the infiltration of myeloid-derived suppressor cells. We conclude that diABZI combined with 1-MT is a promising option for CRC.
|
Authors | Jiaqi Shi, Caiqi Liu, Shengnan Luo, Tingyu Cao, Binlin Lin, Meng Zhou, Xiao Zhang, Song Wang, Tongsen Zheng, Xiaobo Li |
Journal | Cellular immunology
(Cell Immunol)
Vol. 366
Pg. 104384
(08 2021)
ISSN: 1090-2163 [Electronic] Netherlands |
PMID | 34182334
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021 Elsevier Inc. All rights reserved. |
Chemical References |
- 1-methyl-L-tryptophan
- Benzimidazoles
- Immune Checkpoint Inhibitors
- Indoleamine-Pyrrole 2,3,-Dioxygenase
- Membrane Proteins
- Pdcd1 protein, mouse
- Programmed Cell Death 1 Receptor
- Sting1 protein, mouse
- Tryptophan
|
Topics |
- Adenocarcinoma
(drug therapy)
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology, therapeutic use)
- Benzimidazoles
(pharmacology, therapeutic use)
- CD8-Positive T-Lymphocytes
(immunology)
- Carcinogenesis
- Cell Line, Tumor
- Cell Movement
- Cell Proliferation
- Colorectal Neoplasms
(drug therapy)
- Disease Models, Animal
- Disease Progression
- Female
- Humans
- Immune Checkpoint Inhibitors
(therapeutic use)
- Immunotherapy
(methods)
- Indoleamine-Pyrrole 2,3,-Dioxygenase
(antagonists & inhibitors)
- Membrane Proteins
(agonists)
- Mice
- Mice, Inbred C57BL
- Myeloid-Derived Suppressor Cells
(immunology)
- Neoplasm Transplantation
- Programmed Cell Death 1 Receptor
(antagonists & inhibitors)
- Tryptophan
(pharmacology, therapeutic use)
|